NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a deal with Precision Therapeutics to co-market Rosetta's miRview mets2 assay.

Under the terms of the agreement, the two firms will co-market in the US through July 30, 2014 the microRNA-based assay for the identification of the tumor of origin in cancers of unknown or uncertain primary (CUP). The deal includes certain pre-specified performance milestones.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.